FDA approves BeiGene's Brukinsa in rare blood cancer amid company's US expansion plans

BeiGene has been anything but shy about its US expansion plans centered around blood cancer drug Brukinsa. To see those plans through, BeiGene will have to go right at AbbVie and J&J’s Imbruvica, and Brukinsa now has one more arrow in its quiver as part of that battle.